Milan Sigdel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Milan Sigdel has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Dechao Jiao
Department of Interventional Radiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
4 shared publications - Chengzhi Zhang
Department of Interventional Radiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2 shared publications Madan Sigdel
Faculty of Health Sciences, Pokhara University, Pokhara, Nepal
2 shared publications- Mikias Legesse Gebremedhin
Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China, zzu.edu.cn
2 shared publications Yi Fang
Department of Interventional Radiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2 shared publicationsZhanguo Sun
Department of Interventional Radiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2 shared publications
Latest Publications
- Open Access
- 9 January 2026
- Published by Wiley in Radiology Research and Practice
- Vol. 2026 (1)
Percutaneous Transhepatic Retrieval of Dysfunctional Plastic Biliary Stents
Purpose: To evaluate the safety and efficacy of percutaneous transhepatic retrieval of dysfunctional plastic biliary stent (PBS). Materials and Methods: In this retrospective, single‐center study, clinical and procedural data of 36 patients who underwent percutaneous transhepatic retrieval of dysfunctional PBS between January 2015 and April 2021 were analyzed. The primary outcomes were technical success, clinical success, complications, procedure time, and radiation exposure. The secondary outcomes were biochemical indicators (total bilirubin [TB], direct bilirubin [DB], glutamic transaminase [ALT], and CA‐19‐9) measured before treatment and two weeks posttreatment. Results: Technical and clinical success were both 100%. Minor complications occurred in 4 cases (11.2%), including 3 hemobilia (Grade 1) and 1 mild cholangitis (Grade 2). The mean procedure time was 39.22 ± 9.34 minutes, with no statistical significance between benign and malignant disease groups ([40.52 ± 9.0] min vs. [38.91 ± 9.5], p = 0.68). The mean radiation exposure was 326.13 ± 206.06 mGy, with no statistical significance between benign and malignant groups ([353.64 ± 258.93] mGy vs. [319.49 ± 196.15] mGy, p > 0.75). Liver functions parameter improved significantly after 2 weeks (TB: [168.31 ± 53.07] vs. [41.70 ± 7.29] μmol/L, DB: [133.51 ± 46.42] vs. [25.39 ± 7.26] μmol/L, ALT: [94.67 ± 38.06] vs. [47.41 ± 13.69] U/L, and CA‐19‐9: [479.11 ± 160.14] vs. [150.72 ± 105.72] U/mL) (all p = 0.01). Conclusion: This study suggests that percutaneous transhepatic retrieval of dysfunctional PBS appears to be a safe and effective alternative when ERCP is not feasible. However, given the retrospective single‐center design, limited sample size, and short follow‐up, larger multicenter studies with longer observation are needed to validate these findings.
- 9 January 2026
- Published by Wiley in Radiology Research and Practice
- Vol. 2026 (1)
Open AccessPercutaneous Transhepatic Retrieval of Dysfunctional Plastic Biliary Stents
Purpose: To evaluate the safety and efficacy of percutaneous transhepatic retrieval of dysfunctional plastic biliary stent (PBS). Materials and Methods: In this retrospective, single‐center study, clinical and procedural data of 36 patients who underwent percutaneous transhepatic retrieval of dysfunctional PBS between January 2015 and April 2021 were analyzed. The primary outcomes were technical success, clinical success, complications, procedure time, and radiation exposure. The secondary outcomes were biochemical indicators (total bilirubin [TB], direct bilirubin [DB], glutamic transaminase [ALT], and CA‐19‐9) measured before treatment and two weeks posttreatment. Results: Technical and clinical success were both 100%. Minor complications occurred in 4 cases (11.2%), including 3 hemobilia (Grade 1) and 1 mild cholangitis (Grade 2). The mean procedure time was 39.22 ± 9.34 minutes, with no statistical significance between benign and malignant disease groups ([40.52 ± 9.0] min vs. [38.91 ± 9.5], p = 0.68). The mean radiation exposure was 326.13 ± 206.06 mGy, with no statistical significance between benign and malignant groups ([353.64 ± 258.93] mGy vs. [319.49 ± 196.15] mGy, p > 0.75). Liver functions parameter improved significantly after 2 weeks (TB: [168.31 ± 53.07] vs. [41.70 ± 7.29] μmol/L, DB: [133.51 ± 46.42] vs. [25.39 ± 7.26] μmol/L, ALT: [94.67 ± 38.06] vs. [47.41 ± 13.69] U/L, and CA‐19‐9: [479.11 ± 160.14] vs. [150.72 ± 105.72] U/mL) (all p = 0.01). Conclusion: This study suggests that percutaneous transhepatic retrieval of dysfunctional PBS appears to be a safe and effective alternative when ERCP is not feasible. However, given the retrospective single‐center design, limited sample size, and short follow‐up, larger multicenter studies with longer observation are needed to validate these findings.
- 4 January 2026
- Published by Elsevier in European Journal of Radiology
- Vol. 195, 112655
Robotic navigation-assisted radio-frequency ablation of lung tumors: a pilot study
- 4 January 2026
- Published by Elsevier in European Journal of Radiology
- Vol. 195, 112655
Robotic navigation-assisted radio-frequency ablation of lung tumors: a pilot study
- 28 October 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (7) , 3982-3991
Efficacy of the EBU Guide Catheter as a Bailout and Selective Strategy in Challenging Right Coronary Artery Interventions
Background: Right coronary artery (RCA) percutaneous coronary intervention (PCI) is often complicated by anatomical factors such as the RCA ostium's variable position within the aortic sinus, the orientation of the proximal RCA segment, aortic root diameter, and lesion complexity that can compromise guide catheter engagement and support. Although the Extra Back‑Up (EBU) catheter is typically used for left coronary interventions, it may have a selective role in RCA PCI, particularly in complex anatomies or as a bailout after failure of standard guides. Methods: We performed a single‐center, retrospective analysis of two cohorts of RCA PCI procedures. The EBU group included 60 RCA PCI procedures performed between 2019 and 2023 where the EBU catheter was used selectively for complex anatomy or after standard catheter failure. The control group comprised 200 consecutive RCA PCI procedues performed in 2023 using standard guide catheters. Primary outcome was catheter success. Secondary outcomes encompassed procedural efficiency and safety endpoints. Results: Catheter success rates did not differ significantly between EBU and standard groups (93.3% vs. 94.5%; p = 0.729), despite a markedly higher prevalence of chronic total occlusions in the EBU cohort (48.3% vs. 15.0%; p < 0.001). Overall complication rates including catheter‐induced dissection, no‐reflow, and general systemic events were low and comparable between cohorts. Operators reported particular EBU utility in low‐sitting and upward‐take‐off RCA ostia. Conclusion: The EBU catheter can be an effective bailout option for RCA PCI after failure of standard guides, demonstrating comparable procedural success and safety in selected appropriate scenarios. Nevertheless, its off‐label use mandates a cautious approach.
- 28 October 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (7) , 3982-3991
Efficacy of the EBU Guide Catheter as a Bailout and Selective Strategy in Challenging Right Coronary Artery Interventions
Background: Right coronary artery (RCA) percutaneous coronary intervention (PCI) is often complicated by anatomical factors such as the RCA ostium's variable position within the aortic sinus, the orientation of the proximal RCA segment, aortic root diameter, and lesion complexity that can compromise guide catheter engagement and support. Although the Extra Back‑Up (EBU) catheter is typically used for left coronary interventions, it may have a selective role in RCA PCI, particularly in complex anatomies or as a bailout after failure of standard guides. Methods: We performed a single‐center, retrospective analysis of two cohorts of RCA PCI procedures. The EBU group included 60 RCA PCI procedures performed between 2019 and 2023 where the EBU catheter was used selectively for complex anatomy or after standard catheter failure. The control group comprised 200 consecutive RCA PCI procedues performed in 2023 using standard guide catheters. Primary outcome was catheter success. Secondary outcomes encompassed procedural efficiency and safety endpoints. Results: Catheter success rates did not differ significantly between EBU and standard groups (93.3% vs. 94.5%; p = 0.729), despite a markedly higher prevalence of chronic total occlusions in the EBU cohort (48.3% vs. 15.0%; p < 0.001). Overall complication rates including catheter‐induced dissection, no‐reflow, and general systemic events were low and comparable between cohorts. Operators reported particular EBU utility in low‐sitting and upward‐take‐off RCA ostia. Conclusion: The EBU catheter can be an effective bailout option for RCA PCI after failure of standard guides, demonstrating comparable procedural success and safety in selected appropriate scenarios. Nevertheless, its off‐label use mandates a cautious approach.
- Open Access
- 1 February 2025
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 15 (2) , 1543-1554
Robotic navigation-assisted percutaneous liver puncture: a pilot study
Background: Liver cancer is often diagnosed at an advanced stage, rendering many cases unresectable and necessitating minimally invasive treatments such as ablation, for which accurate puncture is essential. Manual techniques are limited by steep learning curves, frequent needle adjustments, and increased radiation exposure. Robotic navigation-assisted puncture (RNAP) offers improved precision, efficiency, and safety, but its efficacy compared to that of manual puncture (MP) remains unclear. This study aimed to assess the safety and efficacy of RNAP in the treatment of liver tumors. Methods: From October 2023 to February 2024, 65 patients with liver tumors underwent percutaneous puncture procedures (ablation, iodine-125 implantation, and biopsy) at department of interventional radiology. They were divided into two groups: the RNAP group (n=29) and the MP group (n=36). Two techniques were compared in terms of technical success (TS), clinical success (CS), puncture scoring (PS), number of computed tomography (CT) scans, total procedure time (TPT), puncture time (PT), irradiation dose (ID), and puncture-related complications. Results: There were significant differences between patients in the RNAP group and those in the MP group in terms of PS (3.02±0.68 vs. 2.24±0.73; P=0.01), PT (8.86±1.91 vs. 13.44±3.66 min; P=0.01), number of CT scans (7.03±2.30 vs. 11.58±4.25; P=0.01), and ID (160.76±40.60 vs. 230.06±86.46 mGy·cm; P=0.01); meanwhile, TS (100% vs. 100%; P>0.99), CS (91.50% vs. 91.40%; P=0.81), TPT (33.22±7.80 vs. 32.13±5.50 min; P=0.52), and complications (10.30% vs. 5.56%; P=0.47) showed no differences. Conclusions: RNAP is a useful tool for performing puncture procedures on liver tumors, which can decrease PT, CT scan times, and ID.
- 1 February 2025
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 15 (2) , 1543-1554
Open AccessRobotic navigation-assisted percutaneous liver puncture: a pilot study
Background: Liver cancer is often diagnosed at an advanced stage, rendering many cases unresectable and necessitating minimally invasive treatments such as ablation, for which accurate puncture is essential. Manual techniques are limited by steep learning curves, frequent needle adjustments, and increased radiation exposure. Robotic navigation-assisted puncture (RNAP) offers improved precision, efficiency, and safety, but its efficacy compared to that of manual puncture (MP) remains unclear. This study aimed to assess the safety and efficacy of RNAP in the treatment of liver tumors. Methods: From October 2023 to February 2024, 65 patients with liver tumors underwent percutaneous puncture procedures (ablation, iodine-125 implantation, and biopsy) at department of interventional radiology. They were divided into two groups: the RNAP group (n=29) and the MP group (n=36). Two techniques were compared in terms of technical success (TS), clinical success (CS), puncture scoring (PS), number of computed tomography (CT) scans, total procedure time (TPT), puncture time (PT), irradiation dose (ID), and puncture-related complications. Results: There were significant differences between patients in the RNAP group and those in the MP group in terms of PS (3.02±0.68 vs. 2.24±0.73; P=0.01), PT (8.86±1.91 vs. 13.44±3.66 min; P=0.01), number of CT scans (7.03±2.30 vs. 11.58±4.25; P=0.01), and ID (160.76±40.60 vs. 230.06±86.46 mGy·cm; P=0.01); meanwhile, TS (100% vs. 100%; P>0.99), CS (91.50% vs. 91.40%; P=0.81), TPT (33.22±7.80 vs. 32.13±5.50 min; P=0.52), and complications (10.30% vs. 5.56%; P=0.47) showed no differences. Conclusions: RNAP is a useful tool for performing puncture procedures on liver tumors, which can decrease PT, CT scan times, and ID.
- Open Access
- 3 August 2023
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 40 (1) , 2241687
PVP with or without microwave ablation for the treatment of painful spinal metastases from NSCLC: a retrospective case-control study
To compare the clinical efficacy of percutaneous vertebroplasty (PVP) alone and microwave ablation (MWA) combined with PVP for the treatment of painful spinal metastases from non-small cell lung cancer (NSCLC). From October 2014 to October 2021, the data of 58 NSCLC patients with refractory painful spinal metastases (visual analog scale score ≥ 5) were retrospectively collected and analyzed. Patients in Group A (n = 30) and Group B (n = 28) received PVP alone and MWA combined with PVP, respectively. The primary endpoint was pain relief. The secondary endpoints were quality of life (QoL), local tumor progression (LTP), and complications. The technical success rate was 100% in both groups. Patients in both groups showed similar pain relief at 1-12 weeks, but patients in Group B still showed sustained pain relief at 24 weeks compared to those in Group A (p = 0.03). The assessment of QoL showed similar changes. LTP (33.00% vs. 7.14%, p = 0.02) and cement leakage rates (40.00% vs. 7.14%, p = 0.03) were lower in Group B. The multivariate analysis demonstrated spinal metastases with a maximum diameter ≤ 3.0 cm (p = 0.027) and MWA combined with PVP (p = 0.028) were two independent protective factors for LTP. For cement leakage, spinal metastases with vertebral body compression (p = 0.019) was an independent risk factor, while MWA combined with PVP (p = 0.042) was an independent protective factor. MWA combined with PVP for painful spinal metastases from NSCLC performed more sustained pain relief (>6 months) and ultimately improved QoL with lower LTP and cement leakage rates, compared to PVP alone.
- 3 August 2023
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 40 (1) , 2241687
Open AccessPVP with or without microwave ablation for the treatment of painful spinal metastases from NSCLC: a retrospective case-control study
To compare the clinical efficacy of percutaneous vertebroplasty (PVP) alone and microwave ablation (MWA) combined with PVP for the treatment of painful spinal metastases from non-small cell lung cancer (NSCLC). From October 2014 to October 2021, the data of 58 NSCLC patients with refractory painful spinal metastases (visual analog scale score ≥ 5) were retrospectively collected and analyzed. Patients in Group A (n = 30) and Group B (n = 28) received PVP alone and MWA combined with PVP, respectively. The primary endpoint was pain relief. The secondary endpoints were quality of life (QoL), local tumor progression (LTP), and complications. The technical success rate was 100% in both groups. Patients in both groups showed similar pain relief at 1-12 weeks, but patients in Group B still showed sustained pain relief at 24 weeks compared to those in Group A (p = 0.03). The assessment of QoL showed similar changes. LTP (33.00% vs. 7.14%, p = 0.02) and cement leakage rates (40.00% vs. 7.14%, p = 0.03) were lower in Group B. The multivariate analysis demonstrated spinal metastases with a maximum diameter ≤ 3.0 cm (p = 0.027) and MWA combined with PVP (p = 0.028) were two independent protective factors for LTP. For cement leakage, spinal metastases with vertebral body compression (p = 0.019) was an independent risk factor, while MWA combined with PVP (p = 0.042) was an independent protective factor. MWA combined with PVP for painful spinal metastases from NSCLC performed more sustained pain relief (>6 months) and ultimately improved QoL with lower LTP and cement leakage rates, compared to PVP alone.